← Back to Search

CAR T-cell Therapy

bb21217 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by 2seventy bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must have measurable disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 1 through month 60
Awards & highlights

Study Summary

This trial is testing a new drug for people with multiple myeloma who haven't responded to other treatments.

Eligible Conditions
  • Multiple Myeloma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must have a condition that can be measured or evaluated by the doctors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 1 through month 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 1 through month 60 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events (AEs), DLTs, and changes in laboratory results
Secondary outcome measures
Disease-specific response criteria

Trial Design

1Treatment groups
Experimental Treatment
Group I: bb21217 Experimental ArmExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
bb21217
2017
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

2seventy bioLead Sponsor
2 Previous Clinical Trials
68 Total Patients Enrolled
bluebird bioLead Sponsor
20 Previous Clinical Trials
1,980 Total Patients Enrolled
1 Trials studying Multiple Myeloma
67 Patients Enrolled for Multiple Myeloma
Anna Truppel-Hartmann, MDStudy Directorbluebird bio
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

bb21217 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03274219 — Phase 1
Multiple Myeloma Research Study Groups: bb21217 Experimental Arm
Multiple Myeloma Clinical Trial 2023: bb21217 Highlights & Side Effects. Trial Name: NCT03274219 — Phase 1
bb21217 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03274219 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has bb21217 received clearance from the FDA?

"Our team at Power believes that the safety of bb21217 sits somewhere on a scale from 1 to 3. Due to this being an early-stage Phase I trial, there is limited evidence supporting its efficacy and safety."

Answered by AI

What is the availability of participation slots for this clinical trial?

"As conveyed on clinicaltrials.gov, the recruitment period for this trial has ended; it was originally posted in August 2017 and last updated in March 2021. However, there are 807 other trials recruiting patients at present."

Answered by AI

How many sites are overseeing this clinical experiment?

"A total of 11 medical centres are recruiting participants for this study, including Beth Israel Deaconess Medical Center in Boston, UCSF Medical Center at Parnassus in San Francisco and Massachusetts General Hospital Cancer Centre in Nashville, as well as eight additional sites."

Answered by AI
~9 spots leftby Mar 2025